Recently, Carnobacterium maltaromaticum UAL307, which has been approved in the United States (USDA and FDA) and Canada to preserve processed meat products, was shown to produce at least three bacteriocins: carnocyclin A (CclA), a 60 residue circular peptide, and carnobacteriocin BM1 (CbnBM1) and piscicolin 126 (PisA), which are both type IIa bacteriocins (Martin-Visscher et al., 2008b, 2009). Herein, we evaluate the activity check details of CclA, CbnBM1 and PisA toward three Gram-negative

organisms, at various concentrations, in the absence and presence of EDTA. The activity of these three bacteriocins is compared with that of nisin A (a positive control) and gallidermin, which are both lantibiotics, and to subtilosin A (SubA), which is a 35-residue cyclic peptide with Selleckchem Caspase inhibitor unusual cross-links (Fig. 1). Our report highlights the potential of UAL307 and its bacteriocins for use in alternative strategies to specifically target Gram-negative bacteria. All solutions and

materials were sterilized before use, either by autoclaving (121 °C, 15 min) or by filter sterilization (0.22 μm). Cell buffer contained 50 mM Tris-Cl, pH 7.2, 4 mM CaCl2, 100 mM NaCl and 0.1% gelatin (Stevens et al., 1991). Gram-positive organisms were grown at 25 °C on an all-purpose tween agar or broth, unless otherwise stated. The Gram-negative strains used were Escherichia coli DH5α, Pseudomonas aeruginosa ATCC 14207 and Salmonella Typhimurium ATCC 23564, and were grown on Luria–Bertani (LB) agar or Luria broth at 37 °C. Bacterial cultures were maintained as frozen stocks at −80 °C, in appropriate media supplemented with 20% glycerol. Testing was designed so that equivalent volumes of bacterial culture and bacteriocin testing solutions were mixed. Thus, testing solutions were prepared at twice their desired final concentrations. Two sets of testing solutions were prepared cAMP for each bacteriocin: set A was prepared without EDTA and set B with EDTA (40 mM). For set A, the bacteriocin stock solutions were diluted with cell buffer. For set B, the same bacteriocin stock solutions were diluted with cell buffer containing EDTA. Nisin and gallidermin were tested at final concentrations

of 6.25, 12.5, 25 and 50 μM. CclA, PisA, CbnBM1 and SubA were tested at final concentrations of 0.5, 6.25, 12.5 and 25 μM. A 2.5% preparation of nisin A was purchased (Sigma) and HPLC purified, as described previously (Silkin et al., 2008). A 200 μM stock solution was prepared by dissolving the sample in water. Gallidermin (≥90% purity) was purchased (Axxora) and used without further purification. A 400 μM stock solution was prepared by dissolving the sample in water. CclA was obtained by growing C. maltaromaticum UAL307 and isolating the bacteriocin from the culture supernatant and purifying it to homogeneity by RP-HPLC (Martin-Visscher et al., 2008b). A 200 μM stock solution was prepared by dissolving the peptide in water. CbnBM1 was isolated from C.